Telemedicine

With an increasing demand for cancer care services in a growing population, telemedicine and technology are becoming a vital component of delivering high-quality, value-based cancer care. Innovative e-health platforms and virtual navigation services can improve patient care by mitigating barriers to care for patients who are appropriate for cancer immunotherapy treatment.

Meet the members of the IO Telemedicine Working Group.

Insights from this working group

  • Cancer and Telemedicine
    By Rashid Bashshur, PhD

    When diagnosed with cancer, the typical patient responds with trepidation, anxiety, and fear. This experience engenders a bewildering set of questions, including the cause, treatment options, prognosis, appropriate sources of care, and affordability. Of paramount importance is ready access to expert resources with the requisite knowledge and skill. Telemedicine is a modality of care that addresses all these issues.

  • Virtual Navigation to Clinical Trials
    By Jennifer C. King, PhD

    In the current oncology clinical trials landscape, many barriers remain to clinical trial enrollment that affect both the oncologist and the patient. Among these are trial locations, strict eligibility requirements, insufficient resources to support appropriate clinical trial education and screening, as well as patient and provider attitudes about trials.

  • Telehealth: Partner in Innovation
    By Jennie R. Crews, MD, MMM, FACP
    The paradigm-changing advancements accompanying immunotherapy for cancer continue to require innovation in care delivery. Telehealth is a natural innovation partner for immuno-oncology when applied to patient-reported outcomes, provider education, and clinical trial enrollment.